文献速递骨软组织肉瘤与黑色素瘤

新辅助靶向治疗后病理完全缓解的黑色素瘤组织学特征可预测无复发生存

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma.
PubMed 文献 · Ann Oncol · 2020-07-31

研究回顾两项2期临床试验中接受新辅助达拉非尼联合曲美替尼(DT)治疗的BRAFV600E/K突变可切除III期黑色素瘤患者手术标本,评估病理缓解的组织学特征与无复发生存(RFS)的关系。结果显示达到病理完全缓解(pCR)者RFS更长,但pCR患者中约30%复发;透明性纤维化与更长RFS相关,坏死和/或不成熟/增殖性纤维化与更短RFS相关。多因素分析显示未达pCR或存在不成熟纤维化独立预测更短RFS,pCR患者中成熟/透明性纤维化与改善的RFS相关。

要点

  • 新辅助DT治疗后pCR患者RFS优于非pCR,但仍有30%复发。
  • 透明性纤维化与更长RFS相关,坏死和不成熟纤维化与更短RFS相关。
  • pCR患者中成熟/透明性纤维化与改善RFS相关。

核心结论

  • 新辅助DT治疗后病理缓解的程度和组成与BRAFV600E/K突变黑色素瘤患者的RFS相关,包括pCR患者。

主要发现

  • 达到pCR的患者(49%)RFS长于未达到pCR者(P = 0.005)。
  • 治疗肿瘤显示任何透明性纤维化者RFS长于无透明性纤维化者(P = 0.014)。
  • 坏死(P = 0.012)和/或不成熟/增殖性纤维化(P = 0.026)与更短RFS相关。
  • 多因素分析显示未达pCR或存在不成熟纤维化独立预测更短RFS。
  • pCR患者中成熟/透明性型纤维化与改善的RFS相关(P = 0.035)。

临床怎么用

  • 支持对新辅助治疗后采集的标本进行详细组织学分析以评估复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent clinical trials demonstrated the safety and efficacy of neoadjuvant dabrafenib and trametinib (DT) among patients with surgically resectable clinical stage III BRAFV600E/K mutant melanoma. Although patients achieving a complete pathological response (pCR) exhibited superior recurrence-free survival (RFS) versus those who did not, 30% of pCR patients relapsed. We sought to identify whether histopathological features of the pathological response further delineated risk of relapse. METHODS: Surgical resection specimens from DT-treated patients in two phase 2 clinical trials were reviewed. Histopathological features, including relative amounts of viable tumour, necrosis, melanosis, and fibrosis (hyalinized or immature/proliferative) were assessed for associations with patient outcomes. RESULTS: Fifty-nine patients underwent surgical resection following neoadjuvant DT. Patients achieving pCR (49%) had longer RFS compared with patients who did not (P = 0.005). Patients whose treated tumour showed any hyalinized fibrosis had longer RFS versus those without (P = 0.014), whereas necrosis (P = 0.012) and/or immature/proliferative fibrosis (P = 0.026) correlated with shorter RFS. Multivariable analyses showed absence of pCR or presence of immature fibrosis independently predicted shorter RFS. Among pCR patients, mature/hyalinized-type fibrosis correlated with improved RFS (P = 0.035). CONCLUSIONS: The extent and composition of the pathological response following neoadjuvant DT in BRAFV600E/K mutant melanoma correlates with RFS, including pCR patients. These findings support the need for detailed histological analysis of specimens collected after neoadjuvant therapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Tetzlaff MT, Adhikari C, Lo S, et al. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol. 2020. PMID: 32739408. doi:10.1016/j.annonc.2020.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。